Примери за използване на Fertility study на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
A fertility study in female rats has shown adverse reproductive effects.
Three of 24 male rats treated with high bedaquiline doses failed to produce offspring in the fertility study.
A rat fertility study up to a dose of 1,500 mg/kg/day demonstrated no adverse reactions on either sex.
Non-clinical data revealed no hazard for humans based on a standard male and female fertility study in rats(see section 5.3).
In the rat fertility study, dexmedetomidine had no effect on male or female fertility. .
Reduced fetal body weight was noted also in the rat fertility study at dose 18 µg/kg/day and was accompanied with delayed ossification at dose 54 µg/kg/day.
In a fertility study in male and female rats, female fertility parameters were reduced at dose levels corresponding to human clinical exposures.
No adverse effects were observed in a fertility study in female rats at doses up to 22 times the maximum recommended human dose on a mg/m basis.
In a fertility study in rats, sotagliflozin had no effect on reproductive performance,fertility, and embryo/fetal viability.
Increased post-implantation loss was observed in both the fertility study, which involved treatment of both males and females, and the embryotoxicity study, which involved treatment of females.
A fertility study in female rats resulted in prolonged oestrous cycle and delayed copulation at≥1.5 mg/kg/day lurasidone hydrochloride, whilst the copulation and fertility indices, and the numbers of corpora lutea, implantations and live foetuses were decreased at 150 mg/kg/day lurasidone hydrochloride.
In a combined male/female rat fertility study, baricitinib decreased overall mating performance(decreased fertility and conception indices).
A fertility study in mice, using an analogous antibody that selectively inhibits the functional activity of mouse TNFα, showed no relevant effects on fertility(see section 5.3).
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with indacaterol.
In the fertility study in rats, prolonged and irregular oestrous cycles were observed at the maximum tolerated dose(30 mg/kg) in females; however.
In a rat fertility study, animals dosed up to ten times the clinical dose, no adverse effects on fertility were observed.
In a rat fertility study, during which the animals received up to ten times the clinical dose, no adverse effects on fertility were observed.
A fertility study in rats showed no effect on fertility and mating after intraperitoneal administration of tazobactam or the combination piperacillin/ tazobactam(see section 5.3).
In the fertility study in rats, prolonged and irregular oestrous cycles were observed at high-dose(30 mg/kg) in females; however, these changes did not affect the fertility and early embryonic development.
In a fertility study in rats, marginal reduction in male fertility and pseudopregnancy, protracted periods of diestrus, increased precoital interval and reduced pregnancy rate were seen.
In a rat male fertility study, decreases in epididymides and testes weight were observed but no adverse effects on mating or fertility parameters, and no degeneration or loss in spermatogenesis were observed.
In a female rat fertility study slightly lower numbers of corpora lutea and increased embryolethality were observed in the presence of maternal toxicity(approximately 9.7 times, the human clinical exposure after the third human dose of 3 mg/m2 based on AUC168).
In a fertility study in female rats, ribociclib did not affect reproductive function,fertility or early embryonic development at any dose up to 300 mg/kg/day(which is likely at an exposure lower than or equal to patients' clinical exposure at the highest recommended dose of 600 mg/day based on AUC).
In the dedicated 26-week vismodegib rat fertility study, vismodegib-related effects on female reproductive organs were observed at 100 mg/kg/day immediately after treatment discontinuation, including decreased implantations, increased percent preimplantation loss, and decreased number of dams with viable embryos.
Fertility studies have not been conducted;
Male fertility studies with dabrafenib have not been conducted.
No fertility studies in animals have been performed to evaluate the effect of Alecensa.
Fertility studies with carfilzomib have not been conducted.
No fertility studies in women or men have been conducted.